Arthur F. Golden is a veteran corporate advisor and attorney appointed as a Director on the Board of Turn Therapeutics Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company focused on dermatology, wound care, and infectious disease therapies( He joined the Board in October 2025 to strengthen governance, strategy, and growth amid the company's NASDAQ listing and clinical advancements(

Golden brings over 40 years of experience as a partner at Davis Polk & Wardwell LLP, where he advised Fortune 500 companies and emerging enterprises on M&A, governance, litigation, and risk management across life sciences, healthcare, and other sectors; he currently serves as Senior Counsel there( His career highlights include a 24-year tenure on the Board of Emerson Electric, chairing the Corporate Governance and Finance Committees and serving on the Executive Committee( As a TTRX insider, he has made notable purchases, including 20,202 shares on October 23, 2025, at $4.95 (totaling ~$100,000), and 20,532 shares on November 21, 2025, owning approximately 60,602 shares as of early 2026(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.